US Stock MarketDetailed Quotes
SNPX Synaptogenix
- 2.6000
- +0.0350+1.36%
Close Nov 22 16:00 ET
3.52MMarket Cap2.95P/E (TTM)
2.6000High2.3491Low4.61KVolume2.3491Open2.5650Pre Close11.36KTurnover0.35%Turnover RatioLossP/E (Static)1.36MShares8.775052wk High0.28P/B3.46MFloat Cap2.320052wk Low--Dividend TTM1.33MShs Float362.5000Historical High--Div YieldTTM9.78%Amplitude2.3200Historical Low2.4660Avg Price1Lot Size
About Synaptogenix Company
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.
Company Profile
SymbolSNPX
Company NameSynaptogenix
Listing DateJun 7, 2021
Founded2012
CEODr. Alan J. Tuchman, M.D.
MarketNASDAQ
Employees5
Fiscal Year Ends12-31
Address1185 Avenue of the Americas,3rd floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10036
Phone1-973-242-0005
Websitehttp://www.synaptogen.com
Company Executives
- Name
- Position
- Salary
- Dr. Alan J. Tuchman, M.D.
- Director and Chief Executive Officer
- 303.35K
- Dr. Daniel L. Alkon, M.D.
- Director, President and Chief Scientific Officer
- 375.00K
- Robert Weinstein
- Chief Financial Officer, Secretary, Treasurer, Principal Accounting Officer and Executive Vice President
- 568.92K
- William S. Singer
- Vice Chairman of the Board
- 114.94K
- Joshua Nathaniel Silverman
- Chairman of the Board
- 254.94K
- Jonathan L. Schechter
- Independent Director
- 74.94K
- Bruce T. Bernstein
- Independent Director
- 74.94K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data